A new experimental drug selectively kills the cancerous cells that cause chronic lymphocytic leukemia (CLL). A study shows that PCI-32765 selectively kills the malignant B lymphocytes that cause CLL.
Researchers have developed a treatment that could help minimize nerve damage in spinal cord injuries, promote tissue healing, and minimize pain. The treatment works by reducing production of a protein called RhoA.
Researchers have discovered how the antiviral drug lopinavir attacks HPV by switching on a natural viral defence system in infected cells. The study identifies lopinavir as a potential therapeutic for HPV-related cervical cancer.
Scientists have discovered a way to "wake up" the immune system to fight cancer by delivering an immune system–stimulating protein in a nanoscale container called a vault directly into lung cancer tumors.
JPK Instruments, a manufacturer of nanoanalytic instrumentation for research in life sciences and soft matter, reports that the University of Leipzig has chosen the CellHesion 200 system for their Institute of Experimental Physics I.
Almac’s biocatalysis business has expanded from its 2009 launch to the supply hundreds of kilograms of chiral intermediates for drug substance manufacture and enzyme supply to specialty chemical companies.
Agilent Automation Solutions has released an application note that demonstrates how its Bravo liquid handling system provides an efficient platform for automation of a SISCAPA Magnetic Bead Workflow for protein biomarker quantification by mass spectrometry.
Porvair Filtration Group has announced the launch of the first product, a ChIP kit containing 24 assays, based upon its novel Chromatrap Pro-A Chromatin ImmunoPrecipitation technology.
Daiichi Sankyo Company, Limited announced that it will launch Memary 5mg, 10mg and 20mg Tablets given once daily for the treatment of moderate to severe Alzheimer's Disease.
Molecular Partners AG announced that it has completed two phase 1/2a clinical trials with MP0112, its lead molecule targeting VEGF-alpha. The DARPin molecule was shown to be safe and well tolerated in two separate Phase 1/2a trials.
Beijing Second Pharmaceutical Co., Ltd. has gained U.S. Food and Drug Administration approval of ANDA 090752 for amlodipine besylate, becoming the first Chinese-owned pharma firm to be able to launch an FDA-approved oral solid dose product in the U.S.
Nymox Pharmaceutical Corporation announced that a recent Safety Monitoring Committee meeting found no significant safety concerns to date for its ongoing Phase 3 trials for NX-1207, an investigational drug for benign prostatic hyperplasia.
Hatchtech Pty Ltd has enrolled the first subjects for its Phase 2b clinical study to confirm the efficacy of its novel head lice treatment DeOvo.
Perrigo Co., which makes store-brand, over-the-counter drugs and infant formulas, said its fiscal third-quarter earnings jumped 43 percent, helped by new product sales and gains in some existing categories.